Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, ...

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage ...

Panelists discuss the FDA approval of subcutaneous nivolumab based on the CheckMate-67T trial findings, highlighting its ...

Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of ...

Panelists discuss how the PERSEUS trial demonstrated superior progression-free survival with daratumumab-VRd compared to VRd alone in patients with transplant-eligible newly diagnosed multiple myeloma ...

Panelists discuss how to navigate and choose among multiple guideline-recommended induction regimens for patients with ...

Thomas W. LeBlanc, MD, MA, discusses key clinical pearls for community oncologists in the treatment of anemia in patients with low-risk myelodysplastic syndromes (LR-MDS), including the importance of ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

The LumiSystem is a detection tool that uses fluorescence imaging technology during lumpectomy, offering a more complete resection vs other detection systems that evaluate tissue after surgical ...

The use of radiation therapy has become a staple in breast cancer treatment, with benefits seen in node-positive patients, those with locally advanced disease, and those with large-sized tumors.

Evan Y. Yu, MD, discusses the design and objectives of the phase 3 PEACE 3 study, which evaluates the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor ...